Market Place
Sourcing Support
Cellectis` Cema-Cel Shows Strength In Pivotal Trial Interim Data
13 Apr 2026 //
GLOBENEWSWIRE
Cellectis To Release 2025 Financial Results On March 19, 2026
12 Mar 2026 //
GLOBENEWSWIRE
Cellectis Announces 2026 Strategy And Catalysts
08 Jan 2026 //
GLOBENEWSWIRE
Cellectis Unveils Plan To Boost Eti-Cel Response In R/R NHL
08 Dec 2025 //
GLOBENEWSWIRE
Moligo & Cellectis Show Enzymatic Dna`s Gene Editing Potential
21 Nov 2025 //
PR NEWSWIRE BIO
Cellectis Publish Breakthrough on Non-Viral Gene Editing Process
19 Nov 2025 //
GLOBENEWSWIRE
Cellectis Reveals Q3 2025 Financials and Business Update
07 Nov 2025 //
GLOBENEWSWIRE
Cellectis To Present Development Update For Eti-Cel at ASH 2025
03 Nov 2025 //
GLOBENEWSWIRE
Cellectis To Release Q3 2025 Financial Results On November 7
31 Oct 2025 //
GLOBENEWSWIRE
Cellectis Hosts R&D Day Highlighting Pipeline Progress And Value
16 Oct 2025 //
GLOBENEWSWIRE
Cellectis Showcases Lasme-Cel`s Potential For R/R B-ALL Patients
16 Oct 2025 //
GLOBENEWSWIRE
Factor Bio Files Complaint Against Cellectis & AstraZeneca
26 Sep 2025 //
PR NEWSWIRE
Cellectis Posts Q2 2025 Financial Results and Business Updates
04 Aug 2025 //
GLOBENEWSWIRE
Cellectis` Q2 2025 Financial Results to be Reported on Aug 4
28 Jul 2025 //
GLOBENEWSWIRE
Cellectis Reports Shareholder Meeting Results
26 Jun 2025 //
GLOBENEWSWIRE
Cellectis Annual Shareholders Meeting on June 26, 2025
21 May 2025 //
GLOBENEWSWIRE
Cellectis Reports Financial Results for the First Quarter 2025
12 May 2025 //
GLOBENEWSWIRE
Cellectis to Report Q1 Financial Results on May 12, 2025
06 May 2025 //
GLOBENEWSWIRE
Cellectis Unveils Gene Editing Innovation at ASGCT Meeting
28 Apr 2025 //
GLOBENEWSWIRE
Cellectis to Report Q4 and Full Year 2024 Results on March 13
07 Mar 2025 //
GLOBENEWSWIRE
Cellectis Unveils Strategy For Solid Tumors At AACR-IO 2025
24 Feb 2025 //
GLOBENEWSWIRE
Cellectis Draws €5M from European Investment Bank Credit Facility
10 Dec 2024 //
GLOBENEWSWIRE
Cellectis Presents CAR T-cell Strategies for Solid Tumors
05 Nov 2024 //
GLOBENEWSWIRE
Cellectis drops one of its 3 clinical-stage CAR-Ts
05 Nov 2024 //
FIERCE BIOTECH
Cellectis Reports Q3 2024 Business Updates and Results
04 Nov 2024 //
GLOBENEWSWIRE
Cellectis to Report Q3 2024 Financial Results on November 4, 2024
30 Oct 2024 //
GLOBENEWSWIRE
Cellectis Presents Data On TALE-Base Editors At ESGCT
22 Oct 2024 //
GLOBENEWSWIRE
Cellectis` MUC1 CAR T-cells Show Triple-Negative Breast Cancer Efficacy
03 Sep 2024 //
GLOBENEWSWIRE
Cellectis Publishes Article on SMART DUAL CAR T-cell Approach for Solid Tumors
26 Aug 2024 //
GLOBENEWSWIRE
Cellectis Publishes On SMART DUAL CAR T-Cell Approach For Solid Tumors
26 Aug 2024 //
GLOBENEWSWIRE
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
07 Aug 2024 //
GLOBENEWSWIRE
Cellectis Provides Financial Results for the Second Quarter 2024
06 Aug 2024 //
GLOBENEWSWIRE
Cellectis: Orphan Status For UCART22 In Acute Lymphoblastic Leukemia
04 Jun 2024 //
GLOBENEWSWIRE
Cellectis Novel TALEN Gene Editing Processes At ASGCT
22 Apr 2024 //
GLOBENEWSWIRE
Cellectis Publishes Novel Intronic Gene Editing Approach
10 Apr 2024 //
GLOBENEWSWIRE
AstraZeneca to invest $245 mln in Cellectis to boost gene therapy prospects
02 Nov 2023 //
REUTERS
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program
24 Oct 2023 //
GLOBENEWSWIRE
Cellectis Showcased Preclinical Data at an Oral Presentation at ISCT 2023
05 Jun 2023 //
GLOBENEWSWIRE
Cellectis Provides Business Update and Reports Financial Results for 1Q 2023
04 May 2023 //
GLOBENEWSWIRE
Cellectis Implements CLLS52 for First Time in Clinic with Sanofi`s Alemtuzumab
24 Apr 2023 //
GLOBENEWSWIRE
Cellectis Announces Dosing of the First Patient with Product Candidate UCART22
11 Apr 2023 //
GLOBENEWSWIRE
Cellectis, Primera Partner for Mitochondrial Disease Gene Therapy
02 Jan 2023 //
PHARMA-TECH
